A Multi-Arm Phase 1 Dose Escalation Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of The Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384 In Combination With Experimental Or Approved Anticancer Agents In Patients With Advanced Cancer

Trial Profile

A Multi-Arm Phase 1 Dose Escalation Study Of The Safety, Pharmacokinetics, And Pharmacodynamics Of The Dual PI3K/mTOR Inhibitors PF-04691502 And PF-05212384 In Combination With Experimental Or Approved Anticancer Agents In Patients With Advanced Cancer

Discontinued
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2017

At a glance

  • Drugs Gedatolisib (Primary) ; Irinotecan (Primary) ; PD 325901 (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions
  • Sponsors Pfizer
  • Most Recent Events

    • 24 Oct 2017 Results published in the Targeted Oncology
    • 10 Jun 2017 Biomarkers information updated
    • 13 May 2015 Planned End Date changed from 1 Oct 2015 to 1 Nov 2015 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top